Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDAHeT: Enoxaparin Dose Adjustment in High Risk VTE
NCT04710732Phase 4Terminated
- Sponsor
- Pirogov Russian National Research Medical University
- Start
- Mar 2021
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of enoxaparin in venous thromboembolism (VTE), sponsored by Pirogov Russian National Research Medical University. Started Mar 2021; status: terminated.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT04710732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04710732.